Alphynbiologics
Annapolis, US · Founded 2019 · 4 employees on LinkedIn · 2 known investors
Alphyn Biologics develops Multi-Target Therapeutics based on its Zabalafin (AB-101) platform to treat skin diseases, with a lead candidate, zabalafin hydrogel, a non-steroidal topical treatment for atopic dermatitis in children and adults that targets itch, inflammation, and Staph bacteria. The company operates in the biotech/dermatology drug development sector and has completed a Phase 2a clinical trial.
Founders & leadership
Alphynbiologics was founded in 2019 by Jazmyne Mink.
JM
Jazmyne MinkinCo-founder & Regulatory Affairs Director
GP
Gary PekoeCo-founder & Chief Scientific Officer
NK
Neal KollerCo-founder & CEO, Chairman of the Board
SP
Steven PentelnikCo-founder & President
Investors · 2
Reported raises · per SEC filings
Form D private placements$9.3M disclosed across 4 rounds · 2020–2024
▶$1.2MraisedMay 2024 · 17 investors · BiotechnologyRule 506(b)
▶$1.2MraisedMay 2024 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Steven PentelnikExecutive Officer
- Jeffrey KossakDirector
- Gary PekoeExecutive Officer, Director
- Adel MikhailDirector
- Roger GriggsDirector
- Neal KollerExecutive Officer, Director
- Offering amount
- $1.8M
- Amount sold
- $1.2M
- First sale
- May 2023
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$5.2MraisedApr 2024 · 18 investors · BiotechnologyRule 506(b)
▶$5.2MraisedApr 2024 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Neal KollerExecutive Officer, Director
- Gary PekoeExecutive Officer, Director
- Steven PentelnikDirector
- Roger GriggsDirector
- Jeffrey KossakDirector
- Adel MikhailDirector
- Tony ShipleyDirector
- Offering amount
- $5.2M
- Amount sold
- $5.2M
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$2.2MraisedMay 2022 · 7 investors · BiotechnologyRule 506(b)
▶$2.2MraisedMay 2022 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gary PekoeExecutive Officer, Director
- Neal KollerExecutive Officer, Director
- Offering amount
- $3.5M
- Amount sold
- $2.2M
- Minimum investment
- $10K
- First sale
- May 2022
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$800KraisedFeb 2020 · 5 investors · PharmaceuticalsRule 506(b)
▶$800KraisedFeb 2020 · 5 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Gary PekoeDirector
- Neal KollerExecutive Officer, Director
- Steven PentelnikExecutive Officer, Director
- Offering amount
- $1.5M
- Amount sold
- $800K
- First sale
- Jan 2020
- Incorporated
- Limited Liability Company, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlapAlpyn Beauty4 shared keywordsAlpyn Beauty makes skincare products that combine clinically proven active ingredients with wild-harvested mountain plants from Jackson Hole, Wyoming. Its vegan, cruelty-free line includes serums, cleansers, and creams sold direct to consumers, with a portion of sales donated to national park restoration.
Alnylam4 shared keywordsAlnylam is a biopharmaceutical company that supports investigator-initiated studies in therapeutic areas including transthyretin-mediated amyloidosis, acute hepatic porphyria, and primary hyperoxaluria for medical researchers and healthcare professionals.
IQVIA4 shared keywordsIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
Avalyn Pharma Inc3 shared keywordsAvalyn Pharma develops inhaled therapies for pulmonary fibrosis, using a nebulization approach that delivers treatment directly to the lungs to reduce the tolerability problems of existing oral therapies. The company operates in the biotech and respiratory drug development space.
Companies competing with Alphynbiologics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Alphynbiologics do?
- Alphyn Biologics develops Multi-Target Therapeutics based on its Zabalafin (AB-101) platform to treat skin diseases, with a lead candidate, zabalafin hydrogel, a non-steroidal topical treatment for atopic dermatitis in children and adults that targets itch, inflammation, and Staph bacteria. The company operates in the biotech/dermatology drug development sector and has completed a Phase 2a clinical trial.
- Who founded Alphynbiologics?
- Alphynbiologics was founded by Jazmyne Mink in 2019.
- Who are Alphynbiologics's investors?
- Alphynbiologics's investors include Angel Physicians Fund, QCA First.
- How much funding has Alphynbiologics raised?
- Alphynbiologics has disclosed $9.3M raised across 4 rounds.
- Where is Alphynbiologics headquartered?
- Alphynbiologics is headquartered in Annapolis, US.